Clinical trials: Gram-Positive Bacterial Infections, open to volunteers
Fluoroquinolone, Mycobacterium
Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease
This study is a single-center, open-label clinical trial designed to evaluate the early bactericidal activity (EBA) of sitafloxacin against Mycobacterium abscessus disease.
- Trial name
- NCT06809413
- Testing
- Sitafloxacin
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Chest Hospital
Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
- Trial name
- PRISM (NCT07285213)
- Testing
- AZD5148
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Tuberculosis (TB)
Respiratory Health and Wellbeing Post Pulmonary Tuberculosis
We know that in low-income countries where there is a lot of tuberculosis (TB) about 20%-50% of people treated for TB have long term problems with their lungs and general wellbeing.
- Trial name
- RESPOST (NCT07178860)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Liverpool School of Tropical Medicine
Streptococcus Infection
Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection
Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp.
- Trial name
- CASPR (NCT07335627)
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Strasbourg, France
Tuberculosis, Pulmonary
Post TB Sequelae Study
The goal of this prospective cohort study is to learn about the long-term health effects of tuberculosis (TB) in children, adolescents, and adults who have completed standard TB treatment in Bangladesh.
- Trial name
- NCT06744179
- Testing
- echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire
- Where
- Bangladesh
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
TUBERCULOSIS
Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis
Methodology This is a single-center study carried out as part of routine patient care. The aim of the study is to determine the performance of the 2nd generation TB-IGRA test in the diagnosis of tuberculosis.
- Trial name
- TUBIGRA (NCT06485895)
- Testing
- test IGRA, TEST QUATIFERON TB Gold Plus
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Tuberculosis
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Background: Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This is a paradoxical reaction.
- Trial name
- NCT04052022
- Where
- 3 sites in United States, Mexico
- Volunteers
- 140 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Extrapulmonary Tuberculosis
A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis
This is a prospective, multicenter, observational study (mEX-TB study) of patients with extrapulmonary tuberculosis (EPTB). Adult patients newly diagnosed with EPTB will prospectively be enrolled into the study.
- Trial name
- mEX-TB (NCT06875336)
- Testing
- biomarker analysis
- Where
- 6 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Cologne
Tuberculosis, Latent Tuberculosis
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
- Trial name
- LIMBO-TB (NCT06526689)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary Infection, Pulmonary Nodule
Remimazolam for Bronchoscopy in High-Risk Patients
Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient…
- Conditions
- Pulmonary Infection, Pulmonary Nodule, Phthisis, Endotracheal Tumour
- Trial name
- NCT07395596
- Testing
- propofol and alfentanil, remimazolam combined with propofol and alfentanil
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Sepsis, Tuberculosis
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis
Sepsis, a life-threatening condition due to a dysregulated response to infection, is the leading cause of global mortality and is frequently driven by tuberculosis (TB) and drug-resistant bacteria in sub-Saharan Africa…
- Trial name
- STARS (NCT07332325)
- Testing
- Hydrocortisone administration, Expanded antimicrobial therapy
- Where
- 4 sites in Tanzania, Uganda
- Volunteers
- 344 people
- Sponsor
- University of Virginia
Tuberculosis
Effect of Mycobacterial Infection on Immune Status
This study, titled "Effect of Mycobacterial Infection on Immune Status" (EMIIS), investigates the immune-driven mechanisms of mycobacterial infections, focusing on the dynamic immune characteristics of multidrug-resistant…
- Trial name
- EMIIS (NCT07638670)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Tuberculosis, Pulmonary
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung…
- Trial name
- NCT07077213
- Testing
- 18F-FAPI-74
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Multi Drug Resistant Tuberculosis, HIV Infections
An Adaptive Randomized Controlled Trial
This is a prospective, adaptive, randomized controlled trial comparing the effectiveness of 4 intervention arms on a combined endpoint in adults with confirmed MDR-TB HIV initiating Bedaquiline-containing MDR-TB treatment…
- Trial name
- ADAP-TIV (NCT05633056)
- Testing
- Adherence support intevention
- Where
- South Africa
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Columbia University
Treponema Pallidum, Treponema Pallidum Infection
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA Kit.
- Conditions
- Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum
- Trial name
- NCT07089836
- Testing
- ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
Latent Tuberculosis Infection, Tuberculosis Infection, Latent
Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection
Tuberculosis (TB) is an infectious disease that is caused by bacteria (bugs). The infection is passed on when a patient with active lung TB coughs bugs into the air, which are then breathed in by an uninfected person.
- Trial name
- MICRO-LTBI (NCT06728930)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Queen Mary University of London
Post-COVID / Long-COVID
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
- Trial name
- Monoclonal (NCT07021794)
- Testing
- Sipavibart
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nancy Klimas
Tuberculosis, Pulmonary
Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB
The goal of this interventional trial is to evaluate the safety and efficacy of the loading dose regimen 200/100SPaL-4/13 weeks, and the 100SPaL -17 weeks regimen in adults with newly diagnosed, drug-sensitive, smear-positive…
- Trial name
- NCT07672405
- Testing
- sorfequiline, Pretomanid, Linezolid
- Where
- 12 sites in South Africa, Tanzania
- Volunteers
- 100 people
- Sponsor
- Global Alliance for TB Drug Development
Single Cell Sequencing Technology, Gene Expression Profiling
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.
Febrile illness is a common condition and it is crucial to have an early triage of patients according to various aetiologies to enable appropriate treatment.
- Conditions
- Single Cell Sequencing Technology, Gene Expression Profiling, Gene Expression, Infection
- Trial name
- NCT06846645
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong